Navigation Links
Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
Date:9/7/2011

, including chemotherapeutic agents, radiation, and immunotherapy, work by inducing apoptosis. However, because of molecular alterations in the apoptotic pathways, many cancer cells are resistant or develop resistance to these agents. A promising new direction for drug development involves targeting apoptotic pathways directly to induce cell death and/or restore sensitivity to other treatments. AT-406 was discovered in the laboratory of Dr. Shaomeng Wang at the University of Michigan.

About Debiopharm Group

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm Group is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. For more information on Debiopharm Group™, please visit: http://www.debiopharm.com

About Ascenta Therapeutics, Inc.

Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis). Locust Walk Partners served as exclusive transaction advisor to Asc
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Brook, NY (PRWEB) August 01, 2014 ... @APDN), a provider of DNA-based anti-counterfeiting technology and product ... August 12, 2014 to discuss its fiscal third quarter ... filed with the SEC by the end of the ... DNA Sciences, Inc. management will host a conference call ...
(Date:8/1/2014)... DUBLIN , Aug. 1, 2014 ... of the "The World Market for Flow ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... instruments that are now an important component of ... advanced diagnostic instruments for cancer diagnostics, but their ...
(Date:8/1/2014)... 1. 2014 As one of the 10 ... Annual Meeting & Clinical Lab Expo is the place ... are introduced to the healthcare world. This year, many ... exhibitors will include the latest diagnostic technology in the ... smartphones and biosensors have enabled the development of "labs-on-a-chip" ...
(Date:8/1/2014)... CHICAGO , Aug. 1, 2014 One ... the rise of personalized medicine, which is the practice ... medical treatments to a patient,s individual biology. Personalized diagnostics—laboratory ... a major role in the lab,s future. This fall, ... will feature the latest science in this exciting field ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3The World Market for Flow Cytometry in IVD Applications 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2
... - Worldwide VELCADE(R) (bortezomib) for Injection sales surpassed $765 ... million in 2007 - ... myeloma, with launch on track for ... (Nasdaq: MLNM ) today reported 2007 non-GAAP net,income of $86.9 million and ...
... Feb. 7 ADVENTRX Pharmaceuticals,Inc. (Amex: ... data from,the Company,s marketing-enabling bioequivalence clinical study ... presentation at the 2008,American Association for Cancer ... 12 - 16, 2008 in San Diego, ...
... Ability to Prevent HIV from Replicating, GAITHERSBURG, ... company developing gene therapies for HIV and genetic,diseases, ... VRX496, a gene,therapy for the treatment of AIDS, ... Infections (CROI) in Boston, MA., "This appears ...
Cached Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
(Date:8/1/2014)... -- Modern humans appear in the fossil record about ... years ago that making art and advanced tools became ... in the journal Current Anthropology finds that ... of testosterone levels at around the same time that ... technological innovation, making art and rapid cultural exchange probably ...
(Date:8/1/2014)... what causes them at the molecular level is even ... created the most detailed map to date of a ... diseases, such as age-related macular degeneration. The high-resolution molecular ... supplies blood and oxygen to the outer retina, itself ... of proteins in different areas of the choroid, the ...
(Date:8/1/2014)... the most diverse families in the ocean today -- ... originated more than 400 million years ago in the ... of its modern members. This Geology study ... online on 25 July 2014, tracks the remarkable evolutionary ... At is origin, the Lucinidae family remained at very ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2A map for eye disease 2Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14
... which cancer cells travel from a tumor site and proliferate ... to cancer patients. According to the National Cancer Institute, most ... Virtually all types of cancer can spread to other parts ... are entrenched in the brain, patients typically have only a ...
... the sensitivity of Australia,s species and ecosystems to climate ... about biodiversity conservation. ,Climate change is likely to ... 2030, lead researcher, CSIRO,s Dr Michael Dunlop said.,By 2070, ... and widespread. Many of the environments our plants and ...
... Researchers at the National Institute of Standards and Technology ... candidate refrigerant fluids with low "global warming potential" (GWP) ... for many decades as well as other desirable ... the most extensive systematic search for a new class ...
Cached Biology News:Fighting melanoma's attraction to the brain 2Major changes needed to protect Australia's species and ecosystems 2New NIST screening method identifies 1,200 candidate refrigerants to combat global warming 2
... The S. pombe Whole Genome ... location analysis of yeast (S. pombe) ... immunoprecipitation (ChIP) with Agilent DNA microarrays. ... reliable binding data with greater true ...
... genomes has allowed the development of the ... The S. enterica Typhimurium (strain LT2) genome ... 4,440 ORFs) and a plasmid, pSLT (93,939 ... have been designed to amplify all putative ...
... own microplate stacker system, offers fast and ... host devices:, , Ultra Evolution , SAFIRE ... and SpectraFluor Plus , LS Series of ... supporting a wide range of detection and ...
... LabX light balance makes your life easier. It ... acquisition and management for one balance. *Instruments supported: ... TOLEDO AX, MX, UMX, AG, XS, XP, PR, SR, ... balances *Job management: ...
Biology Products: